In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Verona Pharma Plc ADR (NASDAQ: VRNA) closed at $38.09 in the last session, up 9.02% from day before closing price of $34.94. In other words, the price has increased by $9.02 from its previous closing price. On the day, 1.41 million shares were traded. VRNA stock price reached its highest trading level at $38.3 during the session, while it also had its lowest trading level at $35.0.
Ratios:
We take a closer look at VRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.03 and its Current Ratio is at 13.03. In the meantime, Its Debt-to-Equity ratio is 1.72 whereas as Long-Term Debt/Eq ratio is at 1.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 03, 2024, initiated with a Overweight rating and assigned the stock a target price of $50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’24 when EBSWORTH DAVID R bought 20,000 shares for $4.44 per share. The transaction valued at 88,800 led to the insider holds 940,003 shares of the business.
ZACCARDELLI DAVID sold 2,400 shares of VRNA for $12,000 on Nov 11 ’24. The President and CEO now owns 15,202,352 shares after completing the transaction at $5.00 per share. On Nov 11 ’24, another insider, Hahn Mark W, who serves as the Chief Financial Officer of the company, sold 2,400 shares for $5.00 each. As a result, the insider received 12,000 and left with 14,291,336 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 3116950528 and an Enterprise Value of 22659719168. For the stock, the TTM Price-to-Sale (P/S) ratio is 548.75 while its Price-to-Book (P/B) ratio in mrq is 23.89. Its current Enterprise Value per Revenue stands at 4029.111 whereas that against EBITDA is -150.766.
Stock Price History:
Over the past 52 weeks, VRNA has reached a high of $40.13, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 15.00%, while the 200-Day Moving Average is calculated to be 74.92%.
Shares Statistics:
According to the various share statistics, VRNA traded on average about 1.01M shares per day over the past 3-months and 1110620 shares per day over the past 10 days. A total of 80.44M shares are outstanding, with a floating share count of 68.82M. Insiders hold about 15.90% of the company’s shares, while institutions hold 67.16% stake in the company. Shares short for VRNA as of 1730332800 were 7522563 with a Short Ratio of 7.43, compared to 1727654400 on 8011882. Therefore, it implies a Short% of Shares Outstanding of 7522563 and a Short% of Float of 9.6.
